InsuletPODD
Market Cap: $15.1B
About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Employees: 3,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
167% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 8 (+5) [Q2]
52% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 71
28% more repeat investments, than reductions
Existing positions increased: 238 | Existing positions reduced: 186
17% more capital invested
Capital invested by funds: $12B [Q1] → $14.1B (+$2.04B) [Q2]
7% more funds holding
Funds holding: 550 [Q1] → 587 (+37) [Q2]
0.74% less ownership
Funds ownership: 100.35% [Q1] → 99.61% (-0.74%) [Q2]
42% less call options, than puts
Call options by funds: $122M | Put options by funds: $210M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Barclays Matt Miksic 59% 1-year accuracy 17 / 29 met price target | 2%upside $220 | Equal-Weight Maintained | 12 Aug 2024 |
BTIG Marie Thibault 86% 1-year accuracy 6 / 7 met price target | 16%upside $250 | Buy Maintained | 9 Aug 2024 |
UBS Matthew Taylor 50% 1-year accuracy 3 / 6 met price target | 4%upside $223 | Neutral Maintained | 9 Aug 2024 |
Canaccord Genuity William Plovanic 50% 1-year accuracy 14 / 28 met price target | 9%upside $234 | Buy Maintained | 23 Jul 2024 |
Financial journalist opinion
Based on 16 articles about PODD published over the past 30 days